EP Patent

EP3928766A1 — Pharmaceutical composition and use thereof

Assigned to Barnas Arian Jankur Can · Expires 2021-12-29 · 4y expired

What this patent protects

The present invention is directed to a pharmaceutical composition, wherein the pharmaceutical composition is an injectable or infusable pharmaceutical composition, the pharmaceutical composition comprising:a) a pharmaceutically acceptable solvent,b) a first compound comprising di…

USPTO Abstract

The present invention is directed to a pharmaceutical composition, wherein the pharmaceutical composition is an injectable or infusable pharmaceutical composition, the pharmaceutical composition comprising:a) a pharmaceutically acceptable solvent,b) a first compound comprising diclofenac and/or lornoxicam or a pharmaceutically acceptable salt or solvate thereof,c) a second compound comprising metamizole or tramadol or a pharmaceutically acceptable salt or solvate thereof, andd) a third compound selected as at least one benzodiazepine or a pharmaceutically acceptable salt or solvate thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3928766A1
Jurisdiction
EP
Classification
Expires
2021-12-29
Drug substance claim
No
Drug product claim
No
Assignee
Barnas Arian Jankur Can
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.